Effect of Chitosan on Health and Obesity

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN96702062

Enrollment

250

Registered

2002-12-16

Start date

2001-11-01

Completion date

Unknown

Last updated

2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity Nutritional, Metabolic, Endocrine Obesity

Interventions

3 g Chitosan daily versus placebo.

Eligibility

Inclusion criteria

Inclusion criteria: 1. Overweight/obese male or female volunteers 2. Aged greater than 18 years 3. Body Mass Index (BMI) between 28 - 50 kg/m^2

Exclusion criteria

Exclusion criteria: Not provided at time of registration

Design outcomes

Primary

Measure	Time frame
The primary aim of the ECHO study was to determine if chitosan was an effective weight loss treatment for people who were overweight or obese. Measures included changes in body weight (kilograms); body mass index, waist circumference; body fat percentage; systolic and diastolic blood pressure; serum cholesterol and lipids; plasma glucose; fat-soluble vitamins; faecal fat losses and health-related quality of life, from baseline to 24 weeks.	—

Measure

Time frame

The primary aim of the ECHO study was to determine if chitosan was an effective weight loss treatment for people who were overweight or obese. Measures included changes in body weight (kilograms); body mass index, waist circumference; body fat percentage; systolic and diastolic blood pressure; serum cholesterol and lipids; plasma glucose; fat-soluble vitamins; faecal fat losses and health-related quality of life, from baseline to 24 weeks.

—

Secondary

Measure	Time frame
Not provided at time of registration	—

Countries

New Zealand

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026